Granted Patent
B2
US 10,202,449 · App. 15/730,218 · Granted Feb 12, 2019
Cachexia treatment
Assignee:
XBIOTECH, INC.
View Patent ↗
Loading inventors, assignments & file history…
Abstract
Administration of an antibody that specifically binds IL-1α is useful for treating cachexia and increasing the lifespan of a subject suffering from cachexia.
Claims (3)
1. A method comprising the step of repeatedly administering to a human subject having a loss of mean body mass caused by a chronic disease an agent which targets interleukin-1 alpha (IL-1α) at least until the subject's lean body mass is increased, wherein the agent which targets IL-1α is an anti-IL-1α antibody.
2. The method of claim 1 , wherein the antibody is a monoclonal antibody.
3. The method of claim 2 , wherein the monoclonal antibody is an IgG1.
Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Jan 4, 2024
From: JANSSEN BIOTECH, INC.
To: XBIOTECH INC.
Reel/Frame 066022/0815 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Feb 10, 2020
From: XBIOTECH INC.
To: JANSSEN BIOTECH, INC.
Reel/Frame 051769/0927 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Oct 11, 2017
From: SIMARD, JOHN
To: XBIOTECH, INC.
Reel/Frame 043840/0340 →
Continuity (3)
Provisional Application
61538309
· Sep 23, 2011
Cited By (1)